AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Alto Neuroscience Inc.
XNYS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00WYFS6S4
21.97▼ 0.23 (-1.04%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
22.20
Day's Range
21.45 – 22.45
52-Week Range
10.18 – 37.48
Volume
379.2K
Avg Volume
665.7K
Share Statistics
Shares Outstanding
Employees
68
Exchange
XNYS
Listed
2024-02-02
Share count as of August 7, 2026

Alto Neuroscience Inc. (ANRO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Alto Neuroscience Inc. (ANRO)
What is Alto Neuroscience Inc.'s Market Cap?
Alto Neuroscience Inc.'s Market Cap is $862.1M, based on as-reported figures from SEC (XBRL) filings.
What is Alto Neuroscience Inc.'s Enterprise Value?
Alto Neuroscience Inc.'s Enterprise Value is $634.6M, based on as-reported figures from SEC (XBRL) filings.
What is Alto Neuroscience Inc.'s EV / EBITDA?
Alto Neuroscience Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Alto Neuroscience Inc.'s Net Income (TTM)?
Alto Neuroscience Inc.'s Net Income (TTM) is -$84.2M, based on as-reported figures from SEC (XBRL) filings.
What is Alto Neuroscience Inc.'s EBITDA?
Alto Neuroscience Inc.'s EBITDA is -$87.6M, based on as-reported figures from SEC (XBRL) filings.
What is Alto Neuroscience Inc.'s Diluted EPS (TTM)?
Alto Neuroscience Inc.'s Diluted EPS (TTM) is -2.15, based on as-reported figures from SEC (XBRL) filings.
What is Alto Neuroscience Inc.'s Net Debt?
Alto Neuroscience Inc.'s Net Debt is -$227.5M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ANROAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Loss on debt extinguishment
Other, net
Total other income, net
Net loss
Change in fair value attributable to instrument specific credit risk
Net loss per share attributable to common stockholders, basic (in dollars per share)
Net loss per share attributable to common stockholders, diluted (in dollars per share)